Idorsia Pursues Strategic Licensing Deal for TRYVIO Amid Restructuring Efforts

Financial Performance:
Idorsia reported a net revenue of CHF 53 million for the first nine months of 2024, with a US GAAP operating loss of CHF 154 million and a non-GAAP operating loss of CHF 248 million1.

TRYVIO (aprocitentan) Progress:
TRYVIO was approved by the US FDA in March 2024 and became commercially available in the US in October 2024. It is also approved in Japan and by the European Commission under the name JERAYGO1 2.

Licensing Deal:
Idorsia is actively pursuing a global licensing deal for TRYVIO to extend its cash runway, which is currently expected to last until the end of 20241 3.

Restructuring Efforts:
The company plans to lay off 270 staff as part of its cost-cutting measures to improve financial sustainability3 4.

Collaborations:
Idorsia has a collaboration with Viatris Inc. for the development and commercialization of selatogrel and cenerimod, which includes an upfront payment of USD 350 million and potential milestone payments2.

Product Portfolio:
QUVIVIQ (daridorexant) has shown positive results in Phase 4 studies and has been approved for the treatment of insomnia in various regions1 2.